Prosecution Insights
Last updated: November 12, 2026

Kymera Therapeutics Inc.

Technology area: Biotechnology & Pharmaceuticals

8 pending office actions • 6 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 16 patents granted in the last 365 days

Analysis

Kymera Therapeutics Inc. has 8 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 8 distinct examiners and 6 distinct art units, showing broad examiner distribution across several technical examination groups.

CHANDRAKUMAR, NIZAL S is the busiest examiner, with 1 pending matter. The data does not identify a dominant examiner, so prosecution management should emphasize consistency in scientific disclosure and claim strategy across the docket.

The greater number of examiners than art units indicates that some examination groups contain matters assigned to different examiners. Counsel should monitor both dimensions when assessing recurring objections, amendment positions, and opportunities for coordinated responses.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

8
Total Pending OAs
4
Non-Final OAs
4
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (25%)
1
Medium (12%)
5
Easy (62%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§102 only1 (12%)
§112 only5 (62%)
Multi-statute (no §101)2 (25%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

8
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

80 h
Manual time on pending OAs
16 h
Time saved (low, 20%)
28 h
Time saved (mid, 35%)
0.7 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
CHANDRAKUMAR, NIZAL S 1 72.6% +18.3%
SAMSELL, RILLA MARIE 1 69.1% +6.4%
MCDOWELL, BRIAN E 1 74.0% +31.3%
SEITZ, ANTHONY JOSEPH 1 68.3% +26.7%
RAO, SAVITHA M 1 60.7% +29.7%
YOO, SUN JAE 1 70.9% +1.0%
CHEN, PO-CHIH 1 74.3% +14.7%
SANCHEZ, JUSTIN CHRISTOPHER 1 87.3% +12.1%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17597631 PROTEIN DEGRADERS AND USES THEREOF SANCHEZ, JUSTIN CHRISTOPHER —

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18453163 CDK2 INHIBITORS AND USES THEREOF SEITZ, ANTHONY JOSEPH 8d overdue
18583347 CRBN LIGANDS AND USES THEREOF MCDOWELL, BRIAN E —

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
18453163 CDK2 INHIBITORS AND USES THEREOF SEITZ, ANTHONY JOSEPH 8d overdue
18912154 IRAK DEGRADERS AND USES THEREOF CHANDRAKUMAR, NIZAL S —
18583347 CRBN LIGANDS AND USES THEREOF MCDOWELL, BRIAN E —
18002116 IRAK DEGRADERS AND USES THEREOF RAO, SAVITHA M —
17597628 FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF CHEN, PO-CHIH —
17597631 PROTEIN DEGRADERS AND USES THEREOF SANCHEZ, JUSTIN CHRISTOPHER —

Top Art Units

Art UnitApps
1624 2
1621 2
1625 1
1629 1
1691 1
1622 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18912154 IRAK DEGRADERS AND USES THEREOF CHANDRAKUMAR, NIZAL S 1625 §112 Non-Final OA — Pending Oct 10, 2024
18704633 TYK2 DEGRADERS AND USES THEREOF SAMSELL, RILLA MARIE 1624 §112 Non-Final OA — Pending Apr 25, 2024
18583347 CRBN LIGANDS AND USES THEREOF MCDOWELL, BRIAN E 1624 §102§112 Non-Final OA — Pending Feb 21, 2024
18453163 CDK2 INHIBITORS AND USES THEREOF SEITZ, ANTHONY JOSEPH 1629 §102§103§112 Final Rejection 8d overdue Pending Aug 21, 2023
18002116 IRAK DEGRADERS AND USES THEREOF RAO, SAVITHA M 1691 §112 Non-Final OA — Pending Dec 16, 2022
17997463 IRAK INHIBITORS AND USES THEREOF YOO, SUN JAE 1621 §112 Final Rejection — Pending Oct 28, 2022
17597628 FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF CHEN, PO-CHIH 1621 §102 Final Rejection — Pending Jan 14, 2022
17597631 PROTEIN DEGRADERS AND USES THEREOF SANCHEZ, JUSTIN CHRISTOPHER 1622 §112 Final Rejection — Pending Jan 14, 2022

Managing Kymera Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Kymera Therapeutics Inc. have?

Kymera Therapeutics Inc. has 8 pending office actions as of November 2026, spread across 6 art units and 8 examiners.

Which USPTO examiner handles the most Kymera Therapeutics Inc. applications?

Nizal S Chandrakumar has the most, with 1 of Kymera Therapeutics Inc.'s pending office actions.

What technology area are Kymera Therapeutics Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month